Rituximab and Other New Anti-CD20 MAbs for Non-Hodgkin’s Lymphoma Treatment

Rituximab and Other New Anti-CD20 MAbs for Non-Hodgkin’s Lymphoma Treatment

Non-Hodgkin’s lymphomas (NHLs) are a heterogeneous group of different haematological cancers with a wide range of aggressiveness. NHLs represent >80% of lymphomas and the majority of NHLs involve B cells. CD20 represents a good target for NHL immunotherapy because it is largely expressed on B cel...

Full description

Bibliographic Details
Main Authors: Letizia Polito, Massimo Bortolotti, Stefania Maiello, Maria Giulia Battelli, Andrea Bolognesi
Format: Article
Language:English
Published: European Medical Journal 2013-10-01
Series:European Medical Journal Oncology
Subjects:
CD20
Immunotherapy
monoclonal antibodies
Non-Hodgkin’s lymphoma
Online Access:http://emjreviews.com/wp-content/uploads/Rituximab-and-Other-New-Anti-Cd20-Mabs-for-Non-Hodgkin%E2%80%99s-Lymphoma-Treatment.pdf

Internet

http://emjreviews.com/wp-content/uploads/Rituximab-and-Other-New-Anti-Cd20-Mabs-for-Non-Hodgkin%E2%80%99s-Lymphoma-Treatment.pdf

Similar Items